Phosphatases: The new brakes for cancer development?

Enzyme Research

Volumn 2012, Issue , 2012, Pages

  Zhang, Qingxiu ^a   Claret, Francois X ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL POLYPHOSPHATE 4 PHOSPHATASE TYPE 2; INOSITOL POLYPHOSPHATE PHOSPHATASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SRC HOMOLOGY 2 CONTAINING INOSITOL 5' PHOSPHATASE; UNCLASSIFIED DRUG;

CANCER INHIBITION; CARCINOGENESIS; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84866604619     PISSN: 20900406     EISSN: 20900414     Source Type: Journal    
DOI: 10.1155/2012/659649     Document Type: Review

References (119)

1. Franke T. F., Kaplan D. R., Cantley L. C., PI3K: downstream AKTion blocks apoptosis. Cell 1997 88 4 435 437 2-s2.0-0030907987 10.1016/S0092-8674(00) 81883-8 (Pubitemid 27154408)
2. Hennessy B. T., Smith D. L., Ram P. T., Lu Y., Mills G. B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery 2005 4 12 988 1004 2-s2.0-32044466838 10.1038/nrd1902
3. Di Cristofano A., Pandolfi P. P., The multiple roles of PTEN in tumor suppression. Cell 2000 100 4 387 390 2-s2.0-0034681264
4. Gewinner C., Wang Z. C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., Barretina J., Lin W. M., Rameh L., Salmena L., Pandolfi P. P., Cantley L. C., Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009 16 2 115 125 2-s2.0-67651148274 10.1016/j.ccr.2009.06.006
5. Fedele C. G., Ooms L. M., Ho M., Vieusseux J., O'Toole S. A., Millar E. K., Lopez-Knowles E., Sriratana A., Gurung R., Baglietto L., Giles G. G., Bailey C. G., Rasko J. E. J., Shields B. J., Price J. T., Majerus P. W., Sutherland R. L., Tiganis T., McLean C. A., Mitchell C. A., Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proceedings of the National Academy of Sciences of the United States of America 2010 107 51 22231 22236 2-s2.0-78650675585 10.1073/pnas.1015245107
6. Boudeau J., Sapkota G., Alessi D. R., LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Letters 2003 546 1 159 165 2-s2.0-0037524354 10.1016/S0014-5793(03)00642-2 (Pubitemid 36782298)
7. Kwiatkowski D. J., Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biology & Therapy 2003 2 5 471 476 2-s2.0-1542577673
8. Manning B. D., Cantley L. C., United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochemical Society Transactions 2003 31 3 573 578 2-s2.0-0038540963 10.1042/BST0310573 (Pubitemid 36750733)
9. Avdulov S., Li S., Michalek V., Burrichter D., Peterson M., Perlman D. M., Manivel J. C., Sonenberg N., Yee D., Bitterman P. B., Polunovsky V. A., Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004 5 6 553 563 2-s2.0-2942544833 10.1016/j.ccr.2004.05.024 (Pubitemid 38748917)
10. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., Pandolfi P. P., The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Medicine 2004 10 5 484 486 2-s2.0-2442648845 10.1038/nm1042 (Pubitemid 38667906)
11. Wendel H. G., De Stanchina E., Fridman J. S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S. W., Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004 428 6980 332 337 2-s2.0-1642586272 10.1038/nature02369 (Pubitemid 38418805)
12. Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S., The protein kinase complement of the human genome. Science 2002 298 5600 1912 1934 2-s2.0-0037032835 10.1126/science.1075762 (Pubitemid 35425239)
13. Shi Y., Assembly and structure of protein phosphatase 2A. Science in China, Series C 2009 52 2 135 146 2-s2.0-62149139644 10.1007/s11427-009-0018-3
14. Millward T. A., Zolnierowicz S., Hemmings B. A., Regulation of protein kinase cascades by protein phosphatase 2A. Trends in Biochemical Sciences 1999 24 5 186 191 2-s2.0-0000714961 10.1016/S0968-0004(99)01375-4 (Pubitemid 29348452)
15. Gao T., Furnari F., Newton A. C., PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Molecular Cell 2005 18 1 13 24 2-s2.0-15944406764 10.1016/j.molcel.2005.03.008 (Pubitemid 40444644)
16. Brognard J., Newton A. C., PHLiPPing the switch on Akt and protein kinase C signaling. Trends in Endocrinology and Metabolism 2008 19 6 223 230 2-s2.0-47249105677 10.1016/j.tem.2008.04.001 (Pubitemid 351993013)
17. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P. P., Pten is essential for embryonic development and tumour suppression. Nature Genetics 1998 19 4 348 355 2-s2.0-0031870959 10.1038/1235 (Pubitemid 28357906)
18. Stambolic V., Suzuki A., De la Pompa J. L., Brothers G. M., Mirtsos C., Sasaki T., Ruland J., Penninger J. M., Siderovski D. P., Mak T. W., Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998 95 1 29 39 2-s2.0-0032475861 10.1016/S0092-8674(00)81780-8 (Pubitemid 28458022)
19. Wu X., Senechal K., Neshat M. S., Whang Y. E., Sawyers C. L., The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America 1998 95 26 15587 15591 2-s2.0-0032431032 10.1073/pnas.95.26.15587 (Pubitemid 29018743)
20. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R., PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997 275 5308 1943 1947 2-s2.0-0030936323 10.1126/science.275.5308.1943 (Pubitemid 27148818)
21. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K. A., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D. H. F., Tavtigian S. V., Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 1997 15 4 356 362 2-s2.0-17144436629 10.1038/ng0497-356 (Pubitemid 27147102)
22. Li D. M., Sun H., TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β Cancer Research 1997 57 11 2124 2129 2-s2.0-0031001041 (Pubitemid 27247025)
23. Liaw D., Marsh D. J., Li J., Dahia P. L. M., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M., Eng C., Parsons R., Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics 1997 16 1 64 67 2-s2.0-0031004088 (Pubitemid 27198157)
24. Marsh D. J., Dahia P. L., Zheng Z., Liaw D., Parsons R., Gorlin R. J., Eng C., Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genetics 1997 16 4 333 334 2-s2.0-0031203265
25. Sansal I., Sellers W. R., The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of Clinical Oncology 2004 22 14 2954 2963 2-s2.0-4344602002 10.1200/JCO.2004.02.141 (Pubitemid 41079915)
26. Terakawa N., Kanamori Y., Yoshida S., Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocrine-Related Cancer 2003 10 2 203 208 2-s2.0-0038274803 10.1677/erc.0.0100203 (Pubitemid 36758649)
27. Wu H., Goel V., Haluska F. G., PTEN signaling pathways in melanoma. Oncogene 2003 22 20 3113 3122 2-s2.0-0038456399 10.1038/sj.onc.1206451 (Pubitemid 36713763)
28. Stemke-Hale K., Gonzalez-Angulo A. M., Lluch A., Neve R. M., Kuo W. L., Davies M., Carey M., Hu Z., Guan Y., Sahin A., Symmans W. F., Pusztai L., Nolden L. K., Horlings H., Berns K., Hung M. C., Van De Vijver M. J., Valero V., Gray J. W., Bernards R., Mills G. B., Hennessy B. T., An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Research 2008 68 15 6084 6091 2-s2.0-51049118140 10.1158/0008-5472.CAN-07-6854
29. Gonzalez-Angulo A. M., agonzalez@mdanderson.org Ferrer-Lozano J., Stemke-Hale K., Sahin A., Liu S., Barrera J. A., Burgues O., Lluch A. M., Chen H., Hortobagyi G. N., Mills G. B., Meric-Bernstam F., PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Molecular Cancer Therapeutics 2011 10 6 1093 1101 10.1158/1535-7163.MCT-10-1089
30. Regina S., Valentin J. B., Lachot S., Lemarié E., Rollin J., Gruel Y., Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clinical Chemistry 2009 55 10 1834 1842 2-s2.0-70349678707 10.1373/clinchem.2009.123695
31. Forgacs E., Biesterveld E. J., Sekido Y., Fong K., Muneer S., Wistuba I. I., Milchgrub S., Brezinschek R., Virmani A., Gazdar A. F., Minna J. D., Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998 17 12 1557 1565 2-s2.0-7844247587 (Pubitemid 28472760)
32. Hosoya Y., Gemma A., Seike M., Kurimoto F., Uematsu K., Hibino S., Yoshimura A., Shibuya M., Kudoh S., Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer 1999 25 2 87 93 2-s2.0-0032806874 10.1016/S0169-5002(99)00052-5 (Pubitemid 29333087)
33. Suzuki H., Freije D., Nusskern D. R., Okami K., Cairns P., Sidransky D., Isaacs W. B., Bova G. S., Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Research 1998 58 2 204 209 2-s2.0-0031964511 (Pubitemid 28047054)
34. Norris F. A., Ungewickell E., Majerus P. W., Inositol hexakisphosphate binds to clathrin assembly protein 3 (AP-3/AP180) and inhibits clathrin cage assembly in vitro. The Journal of Biological Chemistry 1995 270 1 214 217 2-s2.0-0028842364 10.1074/jbc.270.1.214
35. Norris F. A., Atkins R. C., Majerus P. W., The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. The Journal of Biological Chemistry 1997 272 38 23859 23864 2-s2.0-0030863996 10.1074/jbc.272.38.23859 (Pubitemid 27410966)
36. Ferron M., Vacher J., Characterization of the murine Inpp4b gene and identification of a novel isoform. Gene 2006 376 1-2 152 161 2-s2.0-33745129384 10.1016/j.gene.2006.02.022 (Pubitemid 43903577)
37. Westbrook T. F., Martin E. S., Schlabach M. R., Leng Y., Liang A. C., Feng B., Zhao J. J., Roberts T. M., Mandel G., Hannon G. J., DePinho R. A., Chin L., Elledge S. J., A genetic screen for candidate tumor suppressors identifies REST. Cell 2005 121 6 837 848 2-s2.0-20444376939 10.1016/j.cell.2005.03.033 (Pubitemid 40806416)
38. Barnache S., Le Scolan E., Kosmider O., Denis N., Moreau-Gachelin F., Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene 2006 25 9 1420 1423 2-s2.0-33644775504 10.1038/sj.onc.1209187 (Pubitemid 43336471)
39. Naylor T. L., Greshock J., Wang Y., High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Research 2005 7 6 R1186 R1198
40. Bergamaschi A., Kim Y. H., Wang P., Sorlie T., Hernandez-Boussard T., Lonning P. E., Tibshirani R., Borresen-Dale A. L., Pollack J. R., Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes and Cancer 2006 45 11 1033 1040 2-s2.0-33748939380 10.1002/gcc.20366 (Pubitemid 44435537)
41. Chin S. F., Wang Y., Thorne N. P., Teschendorff A. E., Pinder S. E., Vias M., Naderi A., Roberts I., Barbosa-Morais N. L., Garcia M. J., Iyer N. G., Kranjac T., Robertson J. F. R., Aparicio S., Tavaré S., Ellis I., Brenton J. D., Caldas C., Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 2007 26 13 1959 1970 2-s2.0-33947529520 10.1038/sj.onc.1209985 (Pubitemid 46474632)
42. Rakha E. A., El-Sheikh S. E., Kandil M. A., El-Sayed M. E., Green A. R., Ellis I. O., Expression of BRCA1 protein in breast cancer and its prognostic significance. Human Pathology 2008 39 6 857 865 2-s2.0-44649095619 10.1016/j.humpath.2007.10.011
43. Wang Y., Kreisberg J. I., Ghosh P. M., Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Current Cancer Drug Targets 2007 7 6 591 604 2-s2.0-34548397326 10.2174/156800907781662248 (Pubitemid 47358145)
44. Yuan T. L., Cantley L. C., PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008 27 41 5497 5510 2-s2.0-51849111556 10.1038/onc.2008.245
45. Hodgson M. C., Shao L.-J., Frolov A., Li R., Peterson L. E., Ayala G., Ittmann M. M., Weigel N. L., Agoulnik I. U., Irina.Agoulnik@fiu.edu Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Research 2011 71 2 572 582 10.1158/0008-5472.CAN-10-2314
46. Agoulnik I. U., Hodgson M. C., Bowden W. A., Ittmann M. M., INPP4B: the new kid on the PI3K block. Oncotarget 2011 2 4 321 328
47. Damen J. E., Liu L., Rosten P., Humphries R. K., Jefferson A. B., Majerus P. W., Krystal G., The 145-kDa protein induced to associate with She by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Proceedings of the National Academy of Sciences of the United States of America 1996 93 4 1689 1693 2-s2.0-0029978202
48. Ware M. D., Rosten P., Damen J. E., Liu L., Humphries R. K., Krystal G., Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation. Blood 1996 88 8 2833 2840 2-s2.0-0029859565 (Pubitemid 26357363)
49. Kerr W. G., Heller M., Herzenberg L. A., Analysis of lipopolysaccharide- response genes in B-lineage cells demonstrates that they can have differentiation stage-restricted expression and contain SH2 domains. Proceedings of the National Academy of Sciences of the United States of America 1996 93 9 3947 3952 2-s2.0-0029975903 10.1073/pnas.93.9.3947 (Pubitemid 26144228)
50. Lioubin M. N., Algate P. A., Tsai S., Carlberg K., Aebersold R., Rohrschneider L. R., p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes and Development 1996 10 9 1084 1095 2-s2.0-0029665083
51. Zippo A., De Robertis A., Bardelli M., Galvagni F., Oliviero S., Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 2004 103 12 4536 4544 2-s2.0-2942525073 10.1182/blood-2003-11-3827 (Pubitemid 38745981)
52. Tu Z., Ninos J. M., Ma Z., Wang J., Lemos M. P., Desponts C., Ghansah T., Howson J. M., Kerr W. G., Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5 ′ -phosphatase isoform that partners with the Grb2 adapter protein. Blood 2001 98 7 2028 2038 2-s2.0-0035496903 10.1182/blood.V98.7.2028
53. Gupta N., Scharenberg A. M., Fruman D. A., Cantley L. C., Kinet J. P., Long E. O., The SH2 domain-containing inositol 5 ′ -phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during Fc γ RIIb1-mediated inhibition of B cell receptor signaling. The Journal of Biological Chemistry 1999 274 11 7489 7494 2-s2.0-0033548446 10.1074/jbc.274.11.7489 (Pubitemid 29140569)
54. Lucas D. M., Rohrschneider L. R., A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development. Blood 1999 93 6 1922 1933 2-s2.0-0033559308 (Pubitemid 29128494)
55. Liu L., Damen J. E., Ware M. D., Krystal G., Interleukin-3 induces the association of the inositol 5-phosphatase SHIP with SHP2. The Journal of Biological Chemistry 1997 272 17 10998 11001 2-s2.0-0030892128 10.1074/jbc.272.17.10998 (Pubitemid 27184085)
56. Cutler R. L., Liu L., Damen J. E., Krystal G., Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hemopoietic cells. The Journal of Biological Chemistry 1993 268 29 21463 21465 2-s2.0-0027485538 (Pubitemid 23320626)
57. Lioubin M. N., Myles G. M., Carlberg K., Bowtell D., Rohrschneider L. R., Shc, Grb2, Sos1, and a 150-kilodalton tyrosine-phosphorylated protein form complexes with Fms in hematopoietic cells. Molecular and Cellular Biology 1994 14 9 5682 5691 2-s2.0-0027956320 (Pubitemid 24264396)
58. Sly L. M., Ho V., Antignano F., Ruschmann J., Hamilton M., Lam V., Rauh M. J., Krystal G., The role of SHIP in macrophages. Frontiers in Bioscience 2007 12 2836 2848 2-s2.0-34347214070 10.2741/2276
59. Baran C. P., Tridandapani S., Helgason C. D., Humphries R. K., Krystal G., Marsh C. B., The inositol 5 ′ -phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. The Journal of Biological Chemistry 2003 278 40 38628 38636 2-s2.0-0141755271 10.1074/jbc.M305021200 (Pubitemid 37221760)
60. Helgason C. D., Damen J. E., Rosten P., Grewal R., Sorensen P., Chappel S. M., Borowski A., Jirik F., Krystal G., Humphries R. K., Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes and Development 1998 12 11 1610 1620 2-s2.0-2642684541 (Pubitemid 28299513)
61. Zhou P., Kitaura H., Teitelbaum S. L., Krystal G., Ross F. P., Takeshita S., SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27. Journal of Immunology 2006 177 12 8777 8784 2-s2.0-33845431274 (Pubitemid 44893844)
62. Miletic A. V., Anzelon-Mills A. N., Mills D. M., Omori S. A., Pedersen I. M., Shin D. M., Ravetch J. V., Bolland S., Morse H. C., Rickert R. C., Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. The Journal of Experimental Medicine 2010 207 11 2407 2420 2-s2.0-78149294363 10.1084/jem.20091962
63. Sly L. M., Rauh M. J., Kalesnikoff J., Büchse T., Krystal G., SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Experimental Hematology 2003 31 12 1170 1181 2-s2.0-0345097326 10.1016/j.exphem.2003.09.011 (Pubitemid 37510021)
64. Schurmans S., Carrió R., Behrends J., Pouillon V., Merino J., Clément S., The mouse SHIP2 (Inppl1) gene: complementary DNA, genomic structure, promoter analysis, and gene expression in the embryo and adult mouse. Genomics 1999 62 2 260 271 2-s2.0-0033379824 10.1006/geno.1999.5995 (Pubitemid 30053942)
65. Clément S., Krause U., Desmedt F., Tanti J. F., Behrends J., Pesesse X., Sasaki T., Penninger J., Doherty M., Malaisse W., Dumont J. E., Le Marchand-Brustel Y., Erneux C., Hue L., Schurmans S., The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001 409 6816 92 97 2-s2.0-0035804251 10.1038/35051094 (Pubitemid 32098631)
66. Prasad N. K., Tandon M., Handa A., Moore G. E., Babbs C. F., Snyder P. W., Bose S., High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumor Biology 2008 29 5 330 341 2-s2.0-57449108541 10.1159/000172970
67. Prasad N. K., Tandon M., Badve S., Snyder P. W., Nakshatri H., Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 2008 29 1 25 34 2-s2.0-38849148269 10.1093/carcin/bgm213 (Pubitemid 351201738)
68. Yu J., Ryan D. G., Getsios S., Oliveira-Fernandes M., Fatima A., Lavker R. M., MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proceedings of the National Academy of Sciences of the United States of America 2008 105 49 19300 19305 2-s2.0-58049202164 10.1073/pnas.0803992105
69. Barrandon Y., Green H., Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor- α and epidermal growth factor. Cell 1987 50 7 1131 1137 2-s2.0-0023624729
70. Yu J., Peng H., Ruan Q., Fatima A., Getsios S., Lavker R. M., MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase SHIP2. The FASEB Journal 2010 24 10 3950 3959 2-s2.0-77957853315 10.1096/fj.10-157404
71. Lin X. H., Walter J., Scheidtmann K., Ohst K., Newport J., Walter G., Protein phosphatase 2A is required for the initiation of chromosomal DNA replication. Proceedings of the National Academy of Sciences of the United States of America 1998 95 25 14693 14698 2-s2.0-0032411638 10.1073/pnas.95.25. 14693 (Pubitemid 29003692)
72. Ruediger R., Hentz M., Fait J., Mumby M., Walter G., Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigens. Journal of Virology 1994 68 1 123 129 2-s2.0-0028082299
73. Yu X. X., Du X., Moreno C. S., Green R. E., Ogris E., Feng Q., Chou L., McQuoid M. J., Pallas D. C., Methylation of the protein phosphatase 2A catalytic subunit is essential for association of B α regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen. Molecular Biology of the Cell 2001 12 1 185 199 2-s2.0-0035177048 (Pubitemid 32060587)
74. McCright B., Brothman A. R., Virshup D. M., Assignment of human protein phosphatase 2A regulatory subunit genes B56 α B56 β B56 γ B56 δ and B56 ε (PPP2R5A-PPP2R5E), highly expressed in muscle and brain, to chromosome regions 1q41, 11q12, 3p21, 6p21.1, and 7p11.2 → p12. Genomics 1996 36 1 168 170 2-s2.0-0030586955 10.1006/geno.1996.0438 (Pubitemid 26277771)
75. Cho U. S., Morrone S., Sablina A. A., Arroyo J. D., Hahn W. C., Xu W., Structural basis of PP2A inhibition by small t antigen. PLoS Biology 2007 5 8 e202 2-s2.0-39949085631 10.1371/journal.pbio.0050202 (Pubitemid 47328283)
76. Virshup D. M., Shenolikar S., From promiscuity to precision: protein phosphatases get a makeover. Molecular Cell 2009 33 5 537 545 2-s2.0-61649127812 10.1016/j.molcel.2009.02.015
77. Chen J., Martin B. L., Brautigan D. L., Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992 257 5074 1261 1264 2-s2.0-0026786471
78. Letourneux C., Rocher G., Porteu F., B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. The EMBO Journal 2006 25 4 727 738 2-s2.0-33644524383 10.1038/sj.emboj.7600980 (Pubitemid 43292435)
79. Mumby M., PP2A: unveiling a reluctant tumor suppressor. Cell 2007 130 1 21 24 2-s2.0-34447106751 10.1016/j.cell.2007.06.034 (Pubitemid 47031327)
80. Arroyo J. D., Hahn W. C., Involvement of PP2A in viral and cellular transformation. Oncogene 2005 24 52 7746 7755 2-s2.0-27944448894 10.1038/sj.onc.1209038 (Pubitemid 41670676)
81. Eichhorn P. J. A., Creyghton M. P., Bernards R., Protein phosphatase 2A regulatory subunits and cancer. Biochimica et Biophysica Acta 2009 1795 1 1 15 2-s2.0-58049186804 10.1016/j.bbcan.2008.05.005
82. Suganuma M., Fujiki H., Suguri H., Yoshizawa S., Hirota M., Nakayasu M., Ojika M., Wakamatsu K., Yamada K., Sugimura T., Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proceedings of the National Academy of Sciences of the United States of America 1988 85 6 1768 1771 2-s2.0-0024121562 10.1073/pnas.85.6.1768 (Pubitemid 24315763)
83. Ito A., Koma Y. I., Watabe K., A mutation in protein phosphatase type 2A as a cause of melanoma progression. Histology and Histopathology 2003 18 4 1313 1319 2-s2.0-0142031099 (Pubitemid 37265031)
84. Hahn W. C., Dessain S. K., Brooks M. W., King J. E., Elenbaas B., Sabatini D. M., DeCaprio J. A., Weinberg R. A., Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Molecular and Cellular Biology 2002 22 7 2111 2123 2-s2.0-0036118368 10.1128/MCB.22.7.2111- 2123.2002 (Pubitemid 34224619)
85. Yu J., Boyapati A., Rundell K., Critical role for SV40 small-t antigen in human cell transformation. Virology 2001 290 2 192 198 2-s2.0-0035950921 10.1006/viro.2001.1204 (Pubitemid 33141221)
86. Schönthal A. H., Role of serine/threonine protein phosphatase 2A in cancer. Cancer Letters 2001 170 1 1 13 2-s2.0-0035840446 10.1016/S0304-3835(01) 00561-4 (Pubitemid 32607654)
87. Chen W., Possemato R., Campbell K. T., Plattner C. A., Pallas D. C., Hahn W. C., Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004 5 2 127 136 2-s2.0-1442310493 10.1016/S1535-6108(04)00026-1 (Pubitemid 38283799)
88. Dohoney K. M., Guillerm C., Whiteford C., Elbi C., Lambert P. F., Hager G. L., Brady J. N., Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage. Oncogene 2004 23 1 49 57 2-s2.0-0942301178 10.1038/sj.onc.1207005 (Pubitemid 38142239)
89. Li H. H., Cai X., Shouse G. P., Piluso L. G., Liu X., A specific PP2A regulatory subunit, B56 γ mediates DNA damage-induced dephosphorylation of p53 at Thr55. The EMBO Journal 2007 26 2 402 411 2-s2.0-33846542682 10.1038/sj.emboj.7601519 (Pubitemid 46160941)
90. Sablina A. A., Hector M., Colpaert N., Hahn W. C., Identification of PP2A complexes and pathways involved in cell transformation. Cancer Research 2010 70 24 10474 10484 2-s2.0-78650407231 10.1158/0008-5472.CAN-10-2855
91. Wang S. S., Esplin E. D., Li J. L., Huang L., Gazdar A., Minna J., Evans G. A., Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998 282 5387 284 287 2-s2.0-0032500792 10.1126/science.282.5387.284 (Pubitemid 28487198)
92. Calin G. A., Di Iasio M. G., Caprini E., Vorechovsky I., Natali P. G., Sozzi G., Croce C. M., Barbanti-Brodano G., Russo G., Negrini M., Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000 19 9 1191 1195 2-s2.0-0034708257 (Pubitemid 30157549)
93. Ruediger R., Pham H. T., Walter G., Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A β subunit gene. Oncogene 2001 20 15 1892 1899 2-s2.0-0035810043 10.1038/sj.onc.1204279 (Pubitemid 32458699)
94. Tamaki M., Goi T., Hirono Y., Katayama K., Yamaguchi A., PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncology Reports 2004 11 3 655 659 2-s2.0-4644344978
95. Ruediger R., Pham H. T., Walter G., Disruption of protein phosphatase 2a subunit interaction in human cancers with mutations in the A α subunit gene. Oncogene 2001 20 1 10 15 2-s2.0-0035804217 (Pubitemid 32142333)
96. Baysal B. E., Willett-Brozick J. E., Taschner P. E. M., Dauwerse J. G., Devilee P., Devlin B., A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region. European Journal of Human Genetics 2001 9 2 121 129 2-s2.0-0035131433 (Pubitemid 32156693)
97. Jones S., Wang T. L., Shih I. M., Mao T. L., Nakayama K., Roden R., Glas R., Slamon D., Diaz L. A., Vogelstein B., Kinzler K. W., Velculescu V. E., Papadopoulos N., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010 330 6001 228 231 2-s2.0-77957731999 10.1126/science.1196333
98. McConechy M. K., Anglesio M. S., Kalloger S. E., Yang W., Senz J., Chow C., Heravi-Moussavi A., Morin G. B., Mes-Masson A.-M., Bowtell D., Chenevix-Trench G., DeFazio A., Gertig D., Green A., Webb P., Carey M. S., McAlpine J. N., Kwon J. S., Prentice L. M., Boyd N., Shah S. P., Gilks C. B., Huntsman D. G., dhuntsma@bccancer.bc.ca Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. Journal of Pathology 2011 223 5 567 573 10.1002/path.2848
99. Grochola L. F., Vazquez A., Bond E. E., Würl P., Taubert H., Müller T. H., Levine A. J., Bond G. L., Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. Clinical Cancer Research 2009 15 19 6301 6308 2-s2.0-70349656775 10.1158/1078-0432.CCR-09-0797
100. Li M., Makkinje A., Damuni Z., The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. The Journal of Biological Chemistry 1996 271 19 11059 11062 2-s2.0-0029889342 10.1074/jbc.271.19.11059 (Pubitemid 26155931)
101. von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., Grosveld G., can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3 ′ half to different genes: characterization of the set gene. Molecular and Cellular Biology 1992 12 8 3346 3355 2-s2.0-0026693436
102. Shouse G. P., Nobumori Y., Liu X., A B56 γ mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene 2010 29 27 3933 3941 2-s2.0-77954541457 10.1038/onc.2010.161
103. Jin Z., Wallace L., Harper S. Q., Yang J., PP2A:B56 ε a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development. The Journal of Biological Chemistry 2010 285 45 34493 34502 2-s2.0-78049410230 10.1074/jbc.M110.169581
104. Seeling J. M., Miller J. R., Gil R., Moon R. T., White R., Virshup D. M., Regulation of β -catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999 283 5410 2089 2091 2-s2.0-0033605639 10.1126/science.283.5410.2089 (Pubitemid 29161829)
105. Gao Z. H., Seeling J. M., Hill V., Yochum A., Virshup D. M., Casein kinase I phosphorylates and destabilizes the β -catenin degradation complex. Proceedings of the National Academy of Sciences of the United States of America 2002 99 3 1182 1187 2-s2.0-0037022275 10.1073/pnas.032468199 (Pubitemid 34136467)
106. Li X., Yost H. J., Virshup D. M., Seeling J. M., Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus. The EMBO Journal 2001 20 15 4122 4131 2-s2.0-0035423033 10.1093/emboj/20.15.4122 (Pubitemid 32751828)
107. Yang J., Wu J., Tan C., Klein P. S., PP2A: B56E is required for Wnt/ β -catenin signaling during embryonic development. Development 2003 130 23 5569 5578 2-s2.0-0348013155 10.1242/dev.00762 (Pubitemid 37540834)
108. He X., Semenov M., Tamai K., Zeng X., LDL receptor-related proteins 5 and 6 in Wnt/ β -catenin signaling: arrows point the way. Development 2004 131 8 1663 1677 2-s2.0-2342430345 10.1242/dev.01117 (Pubitemid 38559836)
109. MacDonald B. T., Tamai K., He X., Wnt/ β -catenin signaling: components, mechanisms, and diseases. Developmental Cell 2009 17 1 9 26 2-s2.0-67650230896 10.1016/j.devcel.2009.06.016
110. Yeh E., Cunningham M., Arnold H., Chasse D., Monteith T., Ivaldi G., Hahn W. C., Stukenberg P. T., Shenolikar S., Uchida T., Counter C. M., Nevins J. R., Means A. R., Sears R., A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biology 2004 6 4 308 318 2-s2.0-2342526543 10.1038/ncb1110 (Pubitemid 38584820)
111. Arnold H. K., Sears R. C., Protein phosphatase 2A regulatory subunit B56 α associates with c-Myc and negatively regulates c-Myc accumulation. Molecular and Cellular Biology 2006 26 7 2832 2844 2-s2.0-33645232372 10.1128/MCB.26.7.2832-2844.2006
112. Junttila M. R., Puustinen P., Niemelä M., Ahola R., Arnold H., Böttzauw T., Ala-aho R., Nielsen C., Ivaska J., Taya Y., Lu S. L., Lin S., Chan E. K. L., Wang X. J., Grènman R., Kast J., Kallunki T., Sears R., Kähäri V. M., Westermarck J., CIP2A inhibits PP2A in human malignancies. Cell 2007 130 1 51 62 2-s2.0-34447283580 10.1016/j.cell.2007.04. 044 (Pubitemid 47039258)
113. Margolis S. S., Perry J. A., Forester C. M., Nutt L. K., Guo Y., Jardim M. J., Thomenius M. J., Freel C. D., Darbandi R., Ahn J. H., Arroyo J. D., Wang X. F., Shenolikar S., Nairn A. C., Dunphy W. G., Hahn W. C., Virshup D. M., Kornbluth S., Role for the PP2A/B56 δ phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell 2006 127 4 759 773 2-s2.0-33751212191 10.1016/j.cell.2006.10.035 (Pubitemid 44781028)
114. Forester C. M., Maddox J., Louis J. V., Goris J., Virshup D. M., Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1. Proceedings of the National Academy of Sciences of the United States of America 2007 104 50 19867 19872 2-s2.0-38049165541 10.1073/pnas.0709879104
115. Rocher G., Letourneux C., Lenormand P., Porteu F., Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. The Journal of Biological Chemistry 2007 282 8 5468 5477 2-s2.0-34247142858 10.1074/jbc.M609712200 (Pubitemid 47093774)
116. Wu M. X., Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. Apoptosis 2003 8 1 11 18 2-s2.0-0037246194 10.1023/A:1021688600370 (Pubitemid 36133133)
117. Vereshchagina N., Ramel M. C., Bitoun E., Wilson C., The protein phosphatase PP2A- B ′ subunit Widerborst is a negative regulator of cytoplasmic activated Akt and lipid metabolism in Drosophila. Journal of Cell Science 2008 121 20 3383 3392 2-s2.0-56349087537 10.1242/jcs.035220
118. Rodgers J. T., Vogel R. O., Puigserver P., perepuigserver@dfci.harvard. edu Clk2 and B56 β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Molecular Cell 2011 41 4 471 479 10.1016/j.molcel.2011.02.007
119. Mavrakis K. J., Wolfe A. L., Oricchio E., Palomero T., De Keersmaecker K., McJunkin K., Zuber J., James T., Chang K., Khan A. A., Leslie C. S., Parker J. S., Paddison P. J., Tam W., Ferrando A., Wendel H. G., Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature Cell Biology 2010 12 4 372 379 2-s2.0-77950518606 10.1038/ncb2037